On January 15, 2020, the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA are slated to review Intellipharmaceutics International Inc.’s (IPCIF.OB) (IPCI.TO) resubmitted New Drug Application for Aximris XR abuse-deterrent oxycodone hydrochloride extended-release tablets.Aximris XR is proposed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.The FDA had turned down Aximris XR on September 25, 2017. IPCIF.OB closed Monday’s (Dec.30, 2019) trading at $0.58, up 18.82%.